• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cytodyn Inc (OP:CYDY)

    0.2634 -0.0256 (-8.86%)
    Streaming Delayed Price Updated: 3:58 PM EDT, Mar 27, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Cytodyn Inc

    < Previous 1 2 3 4 5 Next >
    News headline image
    CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire, P.C.
    Via Business Wire
    News headline image
    CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire, P.C.
    Via Business Wire
    News headline image
    These 2 Under-The-Radar Stocks Traded More Than $1B Each Last Month ↗
    The month of July saw $37.3 billion in trading volume for stocks that trade on the OTCQK and OTCQB. While some of the stocks that trade over-the-counter are considered penny stocks based on their share... 
    Via Benzinga
    News headline image
    Mortgage Financiers & Crypto Securities Reclaim Their Spots As Most Actively Traded Securities On OTC Markets In June ↗
    Reflecting the expected conditions of a bear market, many of the world’s indices saw a decrease in price throughout June. 
    Via Benzinga
    News headline image
    The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall ↗
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    News headline image
    CYTODYN TECHNOLOGIES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CytoDyn Inc. - CYDY
    From Kahn Swick & Foti, LLC
    Via Business Wire
    News headline image
    These OTC Securities Reported The Most Trading Volume In January – With Possible Sustained Interest In International Operators ↗
    Photo from Jason Briscoe on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
    Via Benzinga
    News headline image
    CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    CytoDyn Cancels Webcast and Live Q/A Scheduled for Today
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    Published Paper Indicates Leronlimab Shows Activity Against 4-Class Drug Resistant HIV-1 From Heavily Treatment Experienced (“HTE") Subjects
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    Leronlimab 14-Week, NASH Clinical Trial Met Primary Endpoint (PDFF) and Secondary Endpoint (cT1) for Per Protocol Population in 350 mg Weekly Dose
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    Two Paths to End the Pandemic but the Hybrid Approach Looks Dominant ↗
    Pfizer (NYSE: PFE) is arguably one of the biggest leaders in COVID-19 technology, whether it’s their vaccine or their newly approved oral antiviral called Paxlovid. The... 
    Via Benzinga
    News headline image
    CytoDyn Announces Favorable Ruling Granting Injunction Against Former CRO
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill Population
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    NASH Phase 2 Trial Open-Label Portion Demonstrates Average 80 msec cT1 Reduction in 50% of Patients and Reduction of Nearly 50 msec in 80% of Patients
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    CytoDyn Submits Protocol with the FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 Population
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    CytoDyn Files for Expanded Access Use of Leronlimab for Multi-Drug Resistance HIV Patients
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    CytoDyn’s CRO in Brazil Met with ANVISA to Modify CD16 Trial for Critically Ill COVID-19 Patients to Expedite Interim Analysis After 51 Patients, Potentially in 1Q2022
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    CytoDyn Submits CMC (Manufacturing) Section of HIV BLA to FDA Under Previously Authorized Rolling Review; Last (Clinical) Section Will Complete Full BLA Submission
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at World Antiviral Congress 2021 Beginning Tomorrow
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    Leronlimab (350 mg) Weekly Use for 14 Weeks in Open Label Arm of NASH Trial Produces Fibrosis Reduction as High as 93 msec Amongst First 15 Patients with Average Reduction of 24 msec
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    CytoDyn Research Paper on Leronlimab Published in Frontiers in Immunology Journal
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    Health Canada Authorizes Emergency Use of Leronlimab for Treatment of First Triple-Negative Breast Cancer Patient in Canada
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    CytoDyn Inc. Announces Adjournment of Annual Meeting of Shareholders to November 24, 2021 Due to Lack of Quorum
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    CytoDyn Announces Delaware Court Has Denied Activist Group’s Motion to Prevent Annual Meeting from Taking Place
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    CytoDyn Alerts Shareholders to Vote on Company’s Proxy Card Ahead of October 28th Annual Meeting
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    Group of CytoDyn Stockholders Comments on Delaware Court Decision
    From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
    Via Business Wire
    News headline image
    Delaware Court Agrees with CytoDyn that Activist Group’s Nominations are Invalid
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    These OTC Markets Securities had the Most Trading Activity in September ↗
    Photo by Annie Spratt on Unsplash As the 3rd quarter came to a close in September, the OTC Markets saw a slight decrease in total trading volume even as companies reported... 
    Via Benzinga
    News headline image
    The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results ↗
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
    Via Benzinga
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.